| Open Document File Size: 524,72 KBShare Result on Facebook
City London / Oxford / / Company Nicholson AG / Pearson / Actelion Pharmaceuticals Ltd. / BioMed Central Ltd / GE / / Continent Europe / / Country United States / / / Event Product Issues / FDA Phase / / Facility University College Medical School / / IndustryTerm Experimental systems / / MedicalCondition gastro-oesophageal reflux / vascular inflammatory and fibrotic processes / organ-based fibrosis / inflammatory arthritis / tumour necrosis / limited cutaneous disease / disease / scleroderma fibroblasts / scleroderma / severe systemic sclerosis / pulmonary arterial hypertension / contraction / much more inflammatory onset / diffuse cutaneous systemic sclerosis / pulmonary fibrosis / fibrous scars / skin disease / blister / fibrotic disease / skin fibrosis / lung fibrosis / scleroderma renal crises / often widespread inflammation / lung disease / diseases / namely diffuse and limited cutaneous disease / epithelial cell injury / inflammatory cells / chronic fibrosis / inflammation / different disease / idiopathic lung fibrosis / connective tissue disease / heterogeneous connective tissue disease / limited cutaneous systemic sclerosis / fibrosis / systemic sclerosis / / MedicalTreatment immunosuppression / antibody therapy / CCR / / NaturalFeature Carulli MT / / Organization African Union / Rheumatology / Royal Free and University College Medical School / ETA / Denton Centre for Rheumatology / / Person Christopher P Denton / Ann Rheum / / Position mouse model / a Cre-Lox strategy / driver / second messenger / mediator / important mediator / Fisher / Corresponding author / / Product cyclophosphamide / CAT-192 / type / / ProgrammingLanguage EC / / Technology Gene expression / transplantation / recombination / CAT / / URL http /
SocialTag |
Available online http://arthritis-research.com/content/9/S2/S6 Review Therapeutic targets in systemic sclerosis Christopher P Denton